PRESS

Munich, September 22, 2025 – Cardiogen GmbH, a preclinical clinical life science company focusing on cardiovascular regeneration and cellular reprogramming, is participating in the BIO-EUROPE Conference 2025 . The conference is an international forum to promote business development between pharmaceutical, financial and biotechnology companies. The event is Europe's largest partnering conference serving the global biotech industry. At this conference leading decision makers of

Munich, August 25, 2025 - Cardiogen GmbH today announced that it has appointed its newly formed Scientific Advisory Board, reflecting the company's entering of the pre- and clinical program. This newly formed Scientific Advisory Board represents a first selection of world class key opinion leaders and clinicians, who either already contributed or are now supporting Cardiogen in the  scientific and clinical development of its regenerative gene therapy in cardiovascular disease

Munich, April 10, 2025 – Cardiogen GmbH, a preclinical clinical life science company focusing on cardiovascular regeneration and cellular...